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Recent immunotherapeutic approaches using adoptive cell therapy, or checkpoint
blockade, have demonstrated the powerful anti-cancer potential of CD8 cytotoxic T-
lymphocytes (CTL). While these approaches have shown great promise, they are only
effective in some patients with some cancers. The potential power, and relative ease, of
therapeutic vaccination against tumour associated antigens (TAA) present in different
cancers has been a long sought-after approach for harnessing the discriminating
sensitivity of CTL to treat cancer and has seen recent renewed interest following
cancer vaccination successes using unique tumour neoantigens. Unfortunately, results
with TAA-targeted “universal” cancer vaccines (UCV) have been largely disappointing.
Infectious disease models have demonstrated that T-cell clonotypes that recognise
the same antigen should not be viewed as being equally effective. Extrapolation of
this notion to UCV would suggest that the quality of response in terms of the T-cell
receptor (TCR) clonotypes induced might be more important than the quantity of the
response. Unfortunately, there is little opportunity to assess the effectiveness of individual
T-cell clonotypes in vivo. Here, we identified effective, persistent T-cell clonotypes in an
HLA A2+ patient following successful tumour infiltrating lymphocyte (TIL) therapy. One
such T-cell clone was used to generate super-agonist altered peptide ligands (APLs).
Further refinement produced an APL that was capable of inducing T-cells in greater
magnitude, and with improved effectiveness, from the blood of all 14 healthy donors
tested. Importantly, this APL also induced T-cells from melanoma patient blood that
exhibited superior recognition of the patient’s own tumour compared to those induced
by the natural antigen sequence. These results suggest that use of APL to skew the
clonotypic quality of T-cells induced by cancer vaccination could provide a promising
avenue in the hunt for the UCV “magic bullet.”
Keywords: altered peptide ligand, T-cell receptor, melanoma, tumour infiltrating lymphocyte, cancer vaccine,
cancer immunotherapy
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INTRODUCTION
Vaccination against infectious diseases has saved billions
of human lives and must rank amongst the very highest
achievements of mankind. The power and relative ease of
therapeutic vaccination against tumour associated antigens
(TAA) has been a long sought-after approach for harnessing the
discriminating sensitivity of the adaptive immune system to treat
cancer. The search for therapeutic cancer vaccines is now more
than four decades old and has been a disappointing failure in
comparison to the enormous success of prophylactic pathogen
immunisation programs. Only two therapeutic cancer vaccines
have been approved by the FDA and neither is widely used. The
first FDA approved therapeutic cancer vaccine, a prostate cancer
vaccine called Sipuleucel-t (Provenge R⃝) (1), was controversial as
although it provided minimal extensions to life, treatment failed
to shrink or eliminate cancer and was ultimately unprofitable.
Talimogene laherparepvec (T-VEC), a herpes simplex type 1
oncolytic viral therapy was recently approved for the treatment of
advanced melanoma, is often referred to as a cancer vaccine (2).
T-VEC enhances clinical responsiveness to checkpoint inhibitor
therapy [reviewed in Dummer et al. (3)].
Recent successes of cancer immunotherapy have renewed
interest in the enormous potential of harnessing the power of the
cancer patient’s own immune system to treat cancer (4). These
encouraging accomplishments, revolving around the systemic
blocking of T-cell checkpoints (5) or equipping patient T-cells
with transgenic, chimeric cancer-targeting receptors prior to
adoptive transfer (6, 7), have seen recent FDA approvals for a
growing list of cancer types but with low eﬃcacy in a subset
of cancers, such as lung, gastric and colorectal malignancies.
Consequently, there is an urgent need to develop new enhanced
strategies to harness the immune system for cancer treatment.
Successes in prophylactic vaccination against tumour antigens
expressed by oncogenic viruses such as human papilloma virus
(8) cannot be extended to most cancers. However, cancers
where the mutational load is high, such as melanoma and
lung cancers (9), are known to often present mutated non-self
antigens at the tumour cell surface. These “neoantigens” can
be used for successful vaccination (10, 11) but the approach
is laborious and highly personalised. However, the success of
vaccine strategies targeting non-self, mutated antigens provides
evidence that the ultimate goal of successfully vaccinating against
cancer using TAA targets that are present in all individuals
across the population, could be possible. Realisation of this goal
will require substantial improvements in current vaccination
strategies. Attempts to enhance cancer vaccination have generally
focused on three main components: antigens, adjuvants and the
mode/site of delivery. The main eﬀectors of any cancer vaccine,
as for other immunotherapy successes (5–7), are probably CD8
T-cells that have the power to identify and destroy cancer cells
directly. Approaches to generate such cells to date have generally
focused on themagnitude of the anti-cancer CD8 T-cell response.
Murine adoptive transfer experiments have demonstrated that T-
cell clonotypes recognising the same antigen can exhibit widely
diﬀerential eﬃcacy in vivo (12). Thus, a more promising strategy
for cancer vaccination might aim to enhance the quality of
the response at the clonotypic level rather than the overall
quantity of response. Induction of superior anti-cancer T-cell
clonotypes obviously requires prior knowledge about what these
clonotypes are. Unfortunately, information on the best TCR
clonotypes, like information on the most eﬀective TAA to target,
is lacking. Here, we identified an eﬀective HLA A∗0201 (HLA
A2 hereafter)-restricted clonotype in the tumour infiltrating
lymphocytes (TILs) that were infused into a Stage IV melanoma
patient prior to complete remission (13). This T-cell clonotype
was used to generate an altered peptide ligand (APL) super-
agonist that induced robust T-cell responses from the PBMC
of 14/14 healthy HLA A2+ individuals. The T-cells induced by
this APL exhibited superior anti-cancer immunity when directly
compared to those induced by the natural antigen in parallel
assays. Importantly, we demonstrated that T-cells induced from
blood of a melanoma patient using this APL were considerably
more potent at recognising autologous tumour cells than those
induced by the natural peptide sequence in parallel assays. These
results highlight the potential importance of considering the
quality of the individual T-cell clonotypes induced during future
approaches to cancer vaccination.
METHODS
Subjects
Anonymised healthy donor blood was procured as “buﬀy coats”
from the Welsh Blood Service (WBS) (Pontyclun, Wales, UK).
TIL infusion product and peripheral blood mononuclear cells
(PBMC) from metastatic melanoma patients were provided
as cryopreserved samples by the Center for Cancer Immune
Therapy (CCIT) (Herlev Hospital, Copenhagen, Denmark).
Patient MM909.24 experienced a complete response to the
TIL-based adoptive cell transfer therapy (ACT) and is cancer-
free 5 years post treatment and MM1413.12 experienced a
partial response after TIL-based (ACT) that is ongoing as
residual disease was resected. MM909.37 succumbed to disease
despite TIL therapy. Detailed information on the treatment
characteristics and clinical outcomes can be found in other
published studies [MM909.24 and MM909.37 in Andersen et al.
(13) and MM1413.12 in Andersen et al. (14)]. Details of the
patient and healthy donor samples and the assays performed in
this study can be found in Table 1.
Cancer Cell Lines
T2 cells were maintained in suspension culture at 37◦C in
R10 media [RPMI 1640 medium supplemented with 10%
foetal bovine serum (FBS), 100 U/mL penicillin, 100µg/mL
streptomycin, and 2mM L-Glutamine (Life Technologies,
Paisley, UK)]. Melanoma cell lines from patients MM909.24
and MM909.37 were cultured as adherent monolayers with R10
medium (RPMI containing 10% FBS) and detached from flasks
using D-PBS with 2mM EDTA. Melanoma line FM79 (+ HLA
A2 transgene) was cultured as for MM909.24 and MM909.37.
T-Cell Clones
HLA A2-EAAGIGILTV (Melan-A residues/ Melanoma Antigen
Recognised by T-cells (MART)-1 residues 26-35) CD8 T-cell
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TABLE 1 | Patient and healthy donor samples and the assays performed.
Donor Status Assay Type Figure
1 Healthy Candidate agonist testing
ELISpot for peptide reactivity
3
3
2 Healthy Candidate agonist testing
ELISpot for peptide reactivity
3
3
3 Healthy Candidate agonist testing
Proliferation
3
4
4 Healthy Candidate agonist testing
Proliferation
3
4
5 Healthy Candidate agonist testing
Proliferation
3
4
6 Healthy EAAGIGILTV and MTSAIGILPV line staining 4
7 Healthy EAAGIGILTV and MTSAIGILPV line staining 4
8 Healthy EAAGIGILTV and MTSAIGILPV line staining 4
9 Healthy EAAGIGILTV and MTSAIGILPV line staining
Clonotyping
4
S6
10 Healthy EAAGIGILTV and MTSAIGILPV line staining
Proliferation
4
4
11 Healthy EAAGIGILTV and MTSAIGILPV line staining
Killing of melanoma
4
5
12 Healthy EAAGIGILTV and MTSAIGILPV line staining 4
13 Healthy EAAGIGILTV and MTSAIGILPV line staining
Phenotyping
MTSAIGILPV tetramer staining
S4
S4
7
14 Healthy EAAGIGILTV and MTSAIGILPV line staining
MTSAIGILPV tetramer staining
5
7
MM909.37 Melanoma
patient
EAAGIGILTV and MTSAIGILPV line staining
Killing of autologous melanoma
8
8
MM1413.12 Melanoma
patient
EAAGIGILTV and MTSAIGILPV line staining 8
clones from patient MM909.24 (ST8.24) or healthy donors
(MEL5, MANUELA, CACTUS and EDDY) were maintained in
culture in T-cell medium (R10 supplemented with 1XMEMnon-
essential amino acids, 1mM sodium pyruvate, 10mM HEPES
buﬀer (Life Technologies), 25 ng/mL IL-15 and 200 IU/mL IL-2
(Aldesleukin, brand name Proleukin R⃝; Prometheus, San Diego,
CA). The MEL5 T-cell clone was isolated as previously described
(15). Several clones expressing the same TCR as ST8.24 have been
generated from patient MM909.24 on independent occasions;
either from autologousmelanoma reactive populations (as shown
in Figure 1A); by isolation with cognate tetramer (16, 17); or by
direct cloning without any prior enrichment as the TIL exhibited
>20% melanoma reactivity. MANUELA, CACTUS, and EDDY
were isolated based on staining with HLA A2-cognate peptide
tetramers followed by cloning, then confirmation of reactivity
toward exogenous peptide. Cloning was performed as previously
described (18). Every 2–3 weeks, clones were expanded with 1.5
× 107 irradiated (3100 cGy) allogeneic PBMCs from three donors
provided by the WBS, in T-cell medium, as above but with 20
IU/mL IL-2, and as previously described (18).
Intracellular Cytokine Staining (ICS)
TIL infusion product was co-incubated with T2 cells and a
range of peptide concentrations (10−5-10−12 M) at 37◦C for
5 h in R5 (RPMI containing 5% FBS) containing GolgiStopTM,
GolgiPlugTM (BD Bioscience, Oxford, UK) according to the
manufacturer’s instructions, and anti-CD107a-PE antibody
(clone H483, BD Bioscience). Cells were then washed and
stained with violet Live/Dead fixable dead cell stain, VIVID
(Life Technologies, Paisley, UK) and for surface markers
with anti-CD3 peridinin chlorophyll protein (PerCP) (clone
BW264/56, Miltenyi Biotech, Bergisch Gladbach, Germany)
and anti-CD8 allophycocyanin (APC)-Vio770 (clone BW135/80,
Miltenyi Biotech) antibodies. Cells were prepared for ICS
by incubating with Cytofix/CytopermTM (BD Biosciences),
according to manufacturer’s instructions, before staining for
20min on ice with anti-IFNγ APC antibody (clone 45-15,
Miltenyi Biotech). Cells were resuspended in FACS buﬀer (PBS
supplemented with 2% FBS) before acquisition on BD FACS
Canto II (BD Biosciences). Data was analysed using FlowJo
Software (TreeStar, Ashland, OR, USA).
Peptide Activation Assays
T-cell clones were cultured in R5 for 24 h prior to assay to
reduce spontaneous activation. Assays were performed overnight
in R5 in 96U well plates with 3 × 105 T-cells and 6 × 105
T2 cells with and without desired peptides. The following day,
supernatants were harvested, diluted with 70 µL R0 (R10 but
without serum) and a half-area-well MIP-1β Enzyme-linked
Immunosorbent Assay (ELISA) was carried out as per the
manufacturer’s instructions (R&D Systems, Minneapolis, MN).
A decamer combinatorial peptide library (Pepscan Presto BV,
Lelystad, The Netherlands) was stored and used as previously
described (19). Individual peptides were synthesised to ≥95%
purity (GL Biochem, Shanghai, China, or Peptide Protein
Research Ltd, Hampshire, UK) stored at−80◦C. All peptides had
a free acid and free amine at the C- and N-terminus respectively.
Polyclonal T-cell populations were cultured overnight in R5
in order to reduce spontaneous activation. The following day
an IFNγ Enzyme-Linked ImmunoSpot (ELISpot) assay was
performed, using Multiscreen plates R⃝ (Millipore, Massachusetts,
MA) as per the manufacturers’ instructions (Mabtech, Nacka
Strand, Sweden). 5 × 104 T-cells were screened against 10
candidate super-agonist peptides (described previously) at a
concentration range of 10−4 to 10−8 mM. ELISpot data was
collected using an ImmunoSpot R⃝ plate reader (CTL, Shaker
Heights, Ohio, OH).
Peptide T-Cell Priming
PBMCs were isolated from “buﬀy coats” using the SepMate
protocol, as per the manufacturer’s instructions (STEMCELL
Technologies, Vancouver, BC, Canada). CD8 T-cells were
positively purified using anti-CD8 microbeads (Miltenyi
Biotech), as per the manufacturer’s instructions. The CD8-
negative cell population was pulsed for 1 h at 37◦C with
peptides of interest at a concentration of 25µM, then irradiated
(3100 cGy) to act as antigen presenting cells. CD8 T-cells were
plated in 1mL of priming media (as for T-cell media with 20
IU/mL of IL-2 and no IL-15) in 24 or 48 well plate at a density of
2 × 106 or 4 × 106 alongside peptide pulsed cells at a density of
3 × 106 and 8 × 106 per well, respectively. Anti-CD28 antibody
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FIGURE 1 | CD8 T-cell clone ST8.24 derived from patient TIL persists in patient blood after complete remission. (A) HLA A2-EAAGIGILTV Melan-A restricted CD8
T-cell clone ST8.24 was isolated from the TIL of a stage IV metastatic melanoma patient MM909.24 who successfully underwent tumour infiltrating lymphocyte (TIL)
therapy. The TCR β chain of ST8.24 was present in the TIL infusion product, and in the blood 6 months post complete remission. (B) in vitro culture of TIL MM909.24
with autologous melanoma leads to expansion of Melan-A tetramer+ cells. TILs were stained prior to culture and at day 10, with irrelevant (preproinsulin,
ALWGPDPAAA) and Melan-A (EAAGIGILTV) PE conjugated tetramers, using an optimised protocol (protein kinase treatment + anti-PE 1◦ antibody + PE conjugated
2◦ antibody). Percentage of cells residing in each gated population is shown. ST8.24 was amongst the expanded EAAGIGILTV tetramer+ T-cells. (C) Recognition by
MM909.24 TIL of EAAGIGILTV peptide or super-agonist FATGIGIITV after 5 h using T2 cells as antigen presenting cells. The percentage of cells producing IFNγ
(intracellular staining) is plotted (minus background IFNγ production by TILs alone) vs. peptide concentration. (D) MIP-1β ELISA of EAAGIGILTV reactive clones ST8.24
and MEL5 vs. EAAGIGILTV and FATGIGIITV peptides at the concentration range shown.
(1µg/mL) (clone CD28.2 Beckman Coulter) was added at the
same time as plating the T-cells with the peptide pulsed PBMCs.
These T-cell “primings” were fed with fresh medium tri-weekly
and from day 14 onwards supplemented with 25 ng/mL of IL-15.
Proliferation Assays
For proliferation assays, polyclonal CD8 T-cell populations
isolated from HLA A2+ healthy individuals were labelled
with 0.1µM carboxyfluorescein succinimidyl ester (CFSE)
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(Thermo Fisher Scientific, Waltham, MA) prior to peptide
priming. Briefly, CD8 T-cells were incubated with CFSE
for 20min at RT, and subsequently quenched with R10
medium, in order to stop the reaction. CD8 T-cells were
then washed and plated in T-cell medium (T-cell media
with 20 IU/mL of IL-2 and no IL-15), alongside peptide
pulsed autologous irradiated CD8 negative populations, as
described above.
Peptide-MHC Tetramer Production and
Staining
Soluble biotinylated peptide-MHC monomers were produced
in-house as previously described (20). Tetramers were assembled
and 5 × 104 T-cells stained with 0.5 µg (10µg/mL) of
tetramer, with respect to pMHC component (17). An
optimal tetramer staining protocol using the protein kinase
inhibitor, Dasatinib (21), and primary unconjugated anti-
PE antibody (22) was used as previously described (23, 24).
Additionally, some samples were also stained with a secondary
PE conjugated antibody to add further fluorescence to the
tetramer stained cells (22). Standard staining did not use PKI
or the anti-PE antibody. T-cell lines were stained with live/dead
stain VIVID, anti-CD3 and anti-CD8 (APC) as above, and
additionally with anti-CD4 fluorescein isothiocyanate (FITC)
(clone BIT4, Miltenyi Biotech), anti-CD14 Pacific Blue (PB)
(clone M5E2, BioLegend) and, anti-CD19 PB (clone HIB19,
BioLegend) antibodies.
Peptide-MHC Binding Assay
T2 cells were plated in a 96U-well plate (2 × 104-1 × 106
per well) in AIM-V serum-free media (Life Technologies).
Peptides of interest were added at concentrations 1, 10, and
100µM, alongside a positive control peptide that binds HLA
A2 (GILGFVFTL) and two non-HLA A2 binding peptides (HLA
B∗3501-HPVGEADYFEY and HLA B∗2705 DRASFIKNL) as
negative controls. The volume of DMSO used per condition was
the same and DMSO alone without peptide was used as a control.
Cells were then incubated overnight at room temperature.
The following day, cells were stained with anti-HLA A2 FITC
antibody (clone BB7.2, BioLegend) and incubated at 37◦C for
1 h. Cells were then washed in PBS and stained with VIVID, as
above. Cells were then washed and resuspended in PBS ready
for acquisition.
Generation of Peptide-MHC Structures
All protein crystals were grown at 18◦C by vapour diﬀusion
via hanging drop technique. One microliter of HLA A2-
MTSAIGILPV (10 mg/mL) in crystallisation buﬀer (10mM
Tris pH 8.1 and 10mM NaCl) was added to 1 µL of screen
solution (20%w/v polyethylene glycol 3350, 0.2M sodium
nitrate, 0.1M BIS-TRIS propane pH 6.5). HLA A2 crystals
grown in the same conditions were crushed until no visible
crystal remained using a MicroBead seed kit (Molecular
Dimensions), and added to the solution. Crystallisation screens
were conducted by hand, and data were collected at 100K
at the Diamond Light Source (DLS), Oxfordshire, UK at a
wavelength of 0.98 Å using an ADSC Q315 CCD detector.
Reflection intensities were estimated using XIA2 (25) and the
data were analysed with SCALA and the CCP4 package (26)
Structures were solved with the molecular replacement using
PHASER (27). Sequences were adjusted with COOT (28) and the
models refined with REFMAC5. Graphical representations were
prepared with PYMOL (29). Crystal contacts were determined
using PYMOL and defined as intermolecular distances <
0.4 Å. The reflection data and final model coordinates
were deposited in the PDB database (HLA A2-MTSAIGILPV,
PDB: 6G3J.
T-Cell Cytotoxic Assay
Cytotoxicity assays were performed as previously described (22).
Briefly, target cells were labelled with 51Cr as sodium chromate
(Perkin Elmer, Waltham, MA) and incubated at 37◦C for 1 h
then washed in R10 medium and incubated in 2mL R10 medium
for a further hour to allow excess 51Cr to leach from the cells.
Target cells (1,000 per well) were incubated with T-cells to give
desired T-cell to cancer cell ratios. Targets were incubated alone
or with lysis buﬀer (5% Triton in H2O) to give spontaneous and
maximum release of 51Cr respectively. After incubation, culture
supernatant was harvested and mixed with 150 µL of Opitphase
Supermix scintillation cocktail (PerkinElmer) and the release of
51Cr measured using a 1450 MicroBeta TriLux (PerkinElmer).
For flow cytometry based killing assays, 5,000 cancer cells were
co-cultured with (experimental (exp.) wells) and without (control
(con.) wells) T-cells in 96U well plates in T-cell media. Prior
to harvesting, 1 × 105 of 0.1µM CFSE labelled C1R cells
were added to each well to act as a reference cell population.
Cells were stained with VIVID, anti-CD3 PerCP, anti-CD4
APC-Vio770 (Miltenyi Biotec), and anti-CD8 APC-Vio770
(Miltenyi Biotec) leaving viable cancer cells and CFSE labelled
CIRs for analysis. Percentage killing was calculated using the
following equation:
% Killing = 100−
((
exp. target cell events ÷ exp. CFSE C1R events
con. target cell events ÷ con. CFSE C1R events
)
× 100
)
TCR Sequencing
TCR sequencing was performed as previously described (17).
RNA extraction was carried out using the RNEasy Micro
kit (Qiagen, Hilden, Germany). cDNA was synthesized using
the 5′/3′ SMARTer kit (Takara Bio, Paris, France). The
SMARTer approach used a Murine Moloney Leukaemia Virus
(MMLV) reverse transcriptase, a 3′ oligo-dT primer and a
5′ oligonucleotide to generate cDNA templates flanked by a
known, universal anchor sequence at the 5′. PCR was then set
up using a single primer pair consisting of TRAC or TRBC-
specific reverse primer and an anchor-specific forward primer
(Takara Bio, Paris, France). All samples were used for the
following PCR reaction: 2.5 µL template cDNA, 0.25 µL High
Fidelity Phusion Taq polymerase, 10 µL 5X Phusion buﬀer,
0.5 µL DMSO (all from Thermo Fisher Scientific, UK), 1 µL
dNTP (50mM each, Life Technologies, Paisley, UK), 1 µL
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of each primer (10µM), and nuclease-free water for a final
reaction volume of 50 µL. Subsequently, 2.5 µL of the first
PCR products were taken out to set up a nested PCR as
above, using a nested primer pair. All nested primers were
flanked with illumina indexes. For both PCR reactions, cycling
conditions were as follows: 5min at 94◦C, 30 cycles of 30 s at
94◦C, 30 s at 63◦C, 90 s at 72◦C, and a final 10min at 72◦C.
The final PCR products were loaded on a 1% agarose gel and
purified with the QIAEX II gel extraction kit (Qiagen, Hilden,
Germany). Purified products were sequenced on an Illumina
MiSeq instrument using the MiSeq v2 reagent kit (Illumina,
Cambridge, UK).
RESULTS
Generation of Optimal Agonists for a T-Cell
Clone Generated From a Patient That
Underwent Successful TIL Therapy
Analysis of T-cells that responded to autologous tumour within
the TIL infusion product used to cure an HLA A2+ stage IV
melanoma patient (code MM909.24), and also in the blood 6
months post cure, identified several persistent TCR clonotypes
(16, 17). Single cell cloning from the TIL infusion product
produced a monoclonal population of one of these persistent
T-cells, ST8.24 (Figure 1A demonstrates the approach). ST8.24
was found to recognise the HLA A2-restricted, Melan-A-derived
peptide EAAGIGILTV, a common tumour associated antigen
expressed by the majority of melanoma tumours (30). Co-
incubation of TIL infusion product with the autologous tumour
for 10 days demonstrated that a significant portion (22%) of
the tumour-expanded TIL infusion product exhibited reactivity
to EAAGIGILTV peptide (Figure 1B); ST8.24 was included in
this EAAGIGILTV tetramer-positive population. Our previous
work on T-cells that recognise EAAGIGILTV identified a novel
super-agonist peptide, FATGIGIITV (bold underlined amino
acids are not found in the germline-encoded natural TAA
protein sequence) that acted as a super-agonist of melanoma-
reactive T-cell clone MEL5 that was grown from a healthy
donor (31). The FATGIGIITV peptide induced greater CD8
T-cell responses to the EAAGIGILTV natural sequence in
6/10 healthy donors (31). FATGIGIITV-primed T-cells also
exhibited enhanced tumoricidal activity when compared to
EAAGIGILTV-primed T-cells (15, 31). We tested how the
FATGIGIITV peptide activated the TIL infusion product used
to successfully cure patient MM909.24. The FATGIGIITV
peptide failed to induce IFNγ production from this TIL
infusion product (Figure 1C). While results confirmed that
FATGIGIITV was a more potent agonist of the MEL5 T-cell
clone, this peptide failed to activate the ST8.24 T-cell clone
that was present in the TIL infusion product and persisted
in patient blood after complete remission (Figure 1D). The
promising results observed in the majority of donors with the
FATGIGIITV super-agonist peptide designed using the healthy
donor-derived MEL5 T-cell encouraged us to search for an
optimal agonist peptide for the ST8.24 T-cell clone by PS-CPL
screening (32, 33).
Super-Agonist Peptide Can Induce Larger
Populations of EAAGIGILTV-Specific
T-Cells From Donor PBMC Than the
Natural Antigen Leading to Enhanced
Killing of Melanoma
Raw data from the ST8.24 PS-CPL screen were used to generate
a ranked list of the top 10 potential ST8.24 agonists predicted
to activate ST8.24 (Figure 2). These peptides were selected
using a CPL-based peptide searching algorithm (available
at https://picpl.arcca.cf.ac.uk/loginform.php) applied to the
decamer peptide universe, and thus they represent the best
possible in silico predicted peptides for a given clone (34).
CD8 T-cell clone ST8.24 showed good sensitivity to the
10 candidate super-agonist peptides when tested by peptide
titration (concentration range 10−7-10−12 M) by MIP-1β ELISA
(Figure 2C). These 10 candidate super-agonists were taken
forward for further study on how APL might aﬀect the
priming of EAAGIGILTV-specific T-cells from two HLA A2+
healthy donors. For these experiments, CD8 T-cells from
each donor were co-cultured with candidate super-agonist
peptides for 14 days as described in the methods section
above and tested for reactivity using HLA A2-EAAGIGILTV
tetramers. In both donors, peptide 5 (MTSAIGILPV) induced
the largest population of HLA A2-EAAGIGILTV tetramer
positive cells compared to the other 9 candidate super-
agonists and the natural EAAGIGILTV itself (Figure 3A,
Supplementary Figure 1). Functional comparison in IFNγ
ELISpot showed that the cells primed with MTSAIGILPV
were capable of recognising the EAAGIGILTV natural peptide.
Encouraged by these initial results, we examined priming by all 10
APL and the wild-type peptide in three further donors. As before,
the MTSAIGILPV was most potent at priming EAAGIGILTV-
tetramer+ T-cells in donors 4 and 5 (Figure 3B). In the remaining
donor (number 3) MTSAIGILPV came a close second behind
the ISTAIGILPV sequence. The percentage of EAAGIGILTV-
tetramer+ cells primed across these 5 individuals were used to
generate a heat bar for the 10 peptides (Figure 3C). The clear
superiority of the MTSAIGILPV caused us to focus on this
peptide going forward.
We next compared the priming of EAAGIGILTV-specific
T-cells in a further 7 diﬀerent HLA A2+ donors with the
MTSAIGILPV APL and the natural sequence over 14 and
28 days (Figure 4A). MTSAIGILPV elicited the expansion
of significantly more EAAGIGILTV-tetramer specific cells
after 14 days than the EAAGIGILTV peptide itself (Paired
one tailed T-test, P ≤ 0.01 ∗∗) in all donors (Figure 4A,
Supplementary Figure 2). Furthermore, after 28 days it was
noted that the size of HLA A2-EAAGIGILTV tetramer positive
cell population increased significantly in the MTSAIGILPV
primed population in all seven donors (P ≤ 0.05 ∗) (Figure 4A,
Supplementary Figure 3). Figure 4B shows a representative
staining. The superior cell expansion with the MTSAIGILPV
peptide prompted us to set up comparative CFSE proliferation
assays alongside the natural EAAGIGILTV peptide and the
widely used heteroclitic analogue peptide ELAGIGILTV that
was designed to enhance HLA binding (30) and that has been
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FIGURE 2 | Combinatorial peptide library (CPL) screening of T-cell clone ST8.24 allowed candidate super-agonist peptides to be designed. (A) Decamer CPL screen
with melanoma and EAAGIGILTV peptide reactive CD8 clone ST8.24, showing the preferred amino acid residue landscape (EAAGIGILTV residues shown in green).
(B) Data from the CPL was used to generate a list of potential super-agonists. Candidate super-agonist peptides are ranked from 1 to 10 with number 1 predicted to
be the most likely to be recognised by ST8.24. Amino acids residues shared with the Melan-A peptide are shown in green. (C) Peptide titrations of 10 candidate
super-agonist and EAAGIGILTV peptides using clone ST8.24. Results expressed as MIP-1β in ng/mL, minus the MIP-1β value of T-cells incubated alone. Non-linear
curves of best-fit are shown.
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used in clinical trials with little success (35). Cells primed with
MTSAIGILPV proliferated to a greater degree compared to
the EAAGIGILTV and ELAGIGILTV peptides in all donors
tested (Figure 4C). Phenotypic analysis of MTSAIGILPV (4.4%
tetramer+) and EAAGIGILTV (0.6% tetramer+) peptide primed
T-cells from donor 13 showed that the enhanced expansion
of EAAGIGILTV-specific T-cells seen with the MTSAIGILPV
peptide at day 28 was not associated with accelerated exhaustion
based on expression of CD45RA, CD45R0, CCR7, and
CD27, as the EAAGIGILTV primed T-cells exhibited a
very similar phenotype (Supplementary Figure 4). Overall, we
conclude that the MTSAIGILPV peptide expands substantially
larger populations of EAAGIGILTV-specific T-cells than the
EAAGIGILTV peptide itself in 13/13 donors tested and that
these T-cell populations exhibited improved recognition of the
natural epitope.
We next performed killing assays to assess whether the
enhanced expansion of EAAGIGILTV specific T-cells seen with
the MTSAIGILPV peptide translated to improved cytotoxicity
of melanoma cells. T-cell lines from donor 11 from the
original 12 donors (Figure 4A, Supplementary Figures 2, 3),
and an additional donor (number 14, MTSAIGILPV 11.1%
tetramer+ compared to 2.7% for EAAGIGILTV, Figure 5),
were used to target allogeneic HLA A2+ melanomas. The
MTSAIGILPV primed lines from donors 11 and 14 killed
significantly more cancer cells than the EAAGIGILTV
primed lines (Figure 5). In light of this, we next sought to
examine why MTSAIGILPV-primed T-cells might expand to
greater numbers.
The Super-Agonist Peptide Exhibits
Improved Binding to HLA, and Is a
Structural Mimic of EAAGIGILTV
One possible explanation for why the MTSAIGILPV peptide
induced more EAAGIGILTV-specific T-cells than the
EAAGIGILTV peptide itself might be because it exhibits
enhanced binding to the HLA A2 restriction element and
would therefore be present on the cell surface at higher
copy number when supplied exogenously. We compared
HLA binding of both peptides to that of the ELAGIGILTV
sequence that was specifically designed to improve this
property by addition of the optimal anchor at position (p)2
(30). MTSAIGILPV exhibited substantially improved binding
compared to EAAGIGILTV, binding almost as well as the
ELAGIGILTV sequence (Figure 6A). The improved binding
of MTSAIGILPV and ELAGIGILTV to HLA A2 likely means
that these peptides will be present at higher surface density
than the natural peptide in comparative assays. To further
explore the nature of HLA A2-MTSAIGILPV interaction and
peptide presentation mode, we solved the structure of the
binary pHLA complex at 2.45 Å (Table 2, Figure 6B). The
optimal position 2 anchors for HLA A2 are L, M and I so it
was not clear why the MTSAIGILPV exhibited such strong
HLA binding. However, the structural analysis demonstrated
that, although the total number of contacts between the peptide
and HLA-binding groove were only marginally greater for
MTSAIGILPV compared to EAAGIGILTV (136 and 134
respectively), the longer side chain of threonine at position 2
in MTSAIGILPV protruded deeper into the HLA B-pocket
than alanine at position 2 in EAAGIGILTV (Figure 6B). This
enhanced tethering at the N-terminal anchor position likely plays
a chief role in enabling MTSAIGILPV to form a more stable
interaction with HLA A2, contributing to the greater observed
immunogenicity of this peptide compared to EAAGIGILTV.
Despite diﬀering in amino acid sequence at 5/10 positions, the
structural analysis also demonstrated that MTSAIGILPV is a
surprisingly close structural mimic of EAAGIGILTV (root mean
square deviation = 0.38 Å), sharing a virtually identical peptide
backbone conformation. The peptides were also remarkably
similar in terms of buried and exposed peptide side chains, with
peptide residues 4, 5, and 6 forming the outward facing central
bulge in the peptide, and residues 1 and 8 also pointing away
from the HLA surface as additional potential TCR contact sites.
Thus, the structural analysis provides a molecular basis for why
MTSAIGILPV is more stably presented than EAAGIGILTV,
and why T-cells primed with MTSAIGILPV can recognise
the tumour associated EAAGIGILTV peptide. This structural
analysis provides a molecular basis for why MTSAIGILPV is
more stably presented than EAAGIGILTV, and why T-cells
primed withMTSAIGILPV can recognise the tumour associated
EAAGIGILTV peptide.
Super-Agonist Tetramer Stains
EAAGIGILTV Specific T-Cells With Greater
Intensity
We have previously established that staining with peptide-
MHC multimers is dependent on the TCR-pMHC aﬃnity
(17, 22, 36) and that optimised staining procedures are required
for staining functional T-cells with very weak TCRs such as
those that predominate in autoimmune T-cell populations (24).
Consequently, the intensity of staining with pMHC multimers
can provide an indication of TCR aﬃnity at the population level.
We next examined how HLA A2-MTSAIGILPV and HLA A2-
EAAGIGILTV tetramers stained EAAGIGILTV-specific T-cell
clones and polyclonal T-cell populations. T-cell clones ST8.24,
MEL5, MANUELA, CACTUS, and EDDY exhibited greater
fluorescence intensity with MTSAIGILPV tetramers relative
to the tetramers bearing the natural EAAGIGILTV sequence
(Figure 7A). All five of the aforementioned T-cell clones
recognised the MTSAIGILPV peptide more sensitively than
the EAAGIGILTV peptide in peptide titration assays (ST8.24:
Figure 2, others: Figure 7A). Additionally, T-cell lines from
donors 13 and 14 also stained with the super-agonist tetramer
with improved intensity relative to the wild-type EAAGIGILTV
tetramer (Figure 7B). Taken together the improved staining seen
with the MTSAIGILPV tetramer was statistically significant
(p = 0.003, Figure 7C) and as equivalent concentrations of
HLA A2-MTSAIGILPV and HLA A2-EAAGIGILTV tetramers
were used for staining the T-cells, these results suggest that
the associated TCRs exhibit stronger interactions with the
super-agonist peptide. These data combined with the enhanced
HLA binding ofMTSAIGILPV peptide, provide insight into the
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FIGURE 3 | Melan-A tetramer staining of CD8 T-cells primed from healthy HLA A2+ donors with candidate super-agonist peptides. (A) CD8 T-cells isolated from five
healthy donors were primed with wild-type (WT) EAAGIGILTV Melan-A peptide, or one of 10 candidate super-agonists (sequences shown in C), and cultured for 2
weeks. Primed T-cells were stained with EAAGIGILTV PE-conjugated tetramers, using an optimised protocol (protein kinase inhibitor treatment + tetramer + anti-PE
1◦ antibody). Percentage of EAAGIGILTV-tetramer positive cells is shown in bar charts. The dashed line aligns with the percentage of tetramer+ cells for the
EAAGIGILTV peptide primed cells. Line graphs show reactivity to WT peptide EAAGIGILTV (at the range of concentrations indicated) of CD8 T-cells primed with
EAAGIGILTV and MTSAIGILPV from donors 1 and 2 in an IFNγ ELISpot. Results are shown as number of spot forming units (SFU) per 50,000 T-cells. (B) Percentage
of EAAGIGILTV-tetramer positive cells primed in three further donors (as in A). (C) Heat bars were generated using MATLAB R2017b and based on the percentage of
EAAGIGILTV-tetramer positive cells (A&B), with a heat bar for all donors combined shown on the right. The colour indicates the relative magnitude of priming,
according to the key. Priming with peptides MTSAIGILPV generated significantly more EAAGIGILTV tetramer positive cells when compared to priming with
EAAGIGILTV (**p < 0.01). Associated flow cytometry data are shown in Supplementary Figure 1.
mechanism underlying the improved priming of EAAGIGILTV-
specific T-cells by the super-agonist peptide across all
donors tested.
Super-Agonist Peptide Prime Melanoma
Patient T-Cells With Improved Efficacy
The MTSAIGILPV super-agonist peptide was capable of
inducing larger EAAGIGILTV-specific T-cell responses in 14/14
healthy donors and the resulting T-cell lines from two donors
that were tested exhibited improved killing of melanoma.
We reasoned that a real test for this peptide would be
to examine whether MTSAIGILPV was better at inducing
melanoma specific T-cells from the blood of cancer patients.
To examine this aspect, we used samples from two HLA A2+
metastatic melanoma patients that were enrolled in clinical
trials at the CCIT at Herlev hospital Copenhagen. Patient
MM909.37 succumbed to disease following TIL-based adoptive
cell therapy (13). Patient MM1413.12 experienced a partial
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FIGURE 4 | Priming CD8 T-cells from healthy donors with super-agonist peptide MTSAIGILPV elicits significantly more EAAGIGILTV-tetramer positive cells. (A) CD8
T-cells from seven additional healthy donors (6-12) were primed with wild type EAAGIGILTV Melan-A peptide or super-agonist MTSAIGILPV. The magnitude of
reactive cells was tested at day 14 and 28 by EAAGIGILTV-tetramer staining, with percentage tetramer+ cells expressed graphically (associated flow cytometry plots
shown in Supplementary Figures 2, 3). The difference in magnitude of EAAGIGILTV-tetramer positive cells elicited by the super-agonist peptide was significantly
greater than EAAGIGILTV primed cells at both time points (paired one-tailed t-test). (NS ≥0.05 *p ≤ 0.05 **p ≤ 0.01). (B) Flow cytometry plots for one donor from (A)
with percentage EAAGIGILTV-tetramer+ cells shown. (C) CFSE proliferation of T-cells primed with wild-type EAAGIGILTV, heteroclitic ELAGIGILTV, or super-agonist
peptide MTSAIGILPV. T-cells were sampled at multiple time points and background proliferation (CFSElow) in the no peptide (DMSO) condition subtracted from the
CFSElow cells in the peptide conditions to give percentage proliferation.
response to TIL therapy and subsequently the remainder of
their tumour resected, the patient is currently tumour-free
with no sign of recurrence. CD8 T-cells isolated from PBMC
samples donated before TIL treatment were primed with
MTSAIGILPV or EAAGIGILTV peptides. Priming of patient-
derived T-cells withMTSAIGILPV super-agonist peptide elicited
a greater magnitude of EAAGIGILTV-tetramer positive cells
than priming with the wild type peptide EAAGIGILTV in both
donors, 0.8% compared to 0.06% in patient MM909.37 and
2.6% compared to 0.5% in patient MM1413.12 (Figure 8A).
For patient MM909.37 there was enough sample to examine
how the primed T-cells responded to the patient’s own tumour
line. T-cells primed with MTSAIGILPV peptide demonstrated
superior lysis of the autologous tumour line compared to T-
cells primed with EAAGIGILTV at a range of T-cell to tumour
ratios during a chromium release assay (Figure 8B). Moreover,
on a per cell basis (two EAAGIGILTV-tetramer positive cells
per three melanoma tumour cells) MTSAIGILPV-primed cells
were significantly better at killing autologous tumour after 4
and 8 h of incubation (P ≤ 0.005 and P ≤ 0.01) compared to
EAAGIGILTV-primed cells (Figure 8C). Unfortunately, PBMCs
from melanoma patients prior to treatment were at a premium
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FIGURE 5 | CD8 T-cells isolated from healthy HLA A2+ donors primed with super-agonist MTSAIGILPV exhibit superior melanoma killing. CD8 T-cells from both
donors 11 and 14 were primed with MTSAIGILPV and EAAGIGILTV peptides and the magnitude of EAAGIGILTV-tetramer positive cells determined on day 14 and 28
for donor 11 (Figure 4, and associated flow cytometry plots in Supplementary Figures 2, 3) and on day 28 only for donor 14 (this figure). (A) Chromium release
cytotoxicity assay performed for the T-cell lines generated from donor 11, with melanoma from patient MM909.24. (B) Peptide priming data (left panel) and flow
cytometry based killing of melanoma tumours FM79 (+HLA A2 transgene) and MM909.24 with the CD8 T-cell lines from donor 14. A ratio of 1 T-cell to 1 tumour cell
was used for both assays.
and we did not generate suﬃcient EAAGIGILTV-specific cells
from patients MM909.37 and MM1413.12 for clonotyping.
Analyses of EAAGIGILTV specific TCRs from EAAGIGILTV
and MTSAIGILPV primed T-cells from donor 9, who had
large EAAGIGILTV-specific populations (Figure 4), revealed
each peptide induced T-cells with diﬀerent TCR clonotypes.
More than half the TCRs from both lines expressed the TRAV12-
2 gene in TCR α chain, which is a bias associated with
HLA A2-EAAGIGILTV specific T-cells (37, 38), but only 2
CDR3α and 1 CDR3β of the total 162 unique CDR3s were
shared between the EAAGIGILTV and MTSAIGILPV lines
(Supplementary Figure 6). Overall, we conclude that super
agonist peptide MTSAIGILPV can prime a greater quantity of
T-cells than is generated by the natural sequence EAAGIGILTV
and that these T-cells can have diﬀerent clonotypes that
may be of a higher quality than those primed with the
natural antigen.
DISCUSSION
Several hurdles need to be overcome before general, non-
personalised cancer vaccines become a reality. First, the best
ubiquitous targets that are widely [over]expressed in cancers but
not healthy cells and that are presented at the cell surface in HLA
class I molecules must be identified. Second, strategies must be
developed to successfully break self-tolerance to such antigens.
Central tolerance is known to delete T-cells that bear a TCR
with high aﬃnity for self-antigens in order to protect against
autoimmunity (39). This process removes the very best TCRs
for recognising TAA leaving those that are on average have a
∼5-fold weaker aﬃnity than receptors that recognise pathogen-
derived, non-self-antigens (40, 41). TCR aﬃnity is known to
govern the functional profile of cancer-specific T-cells (42, 43);
it is also likely to play a pivotal role in whether an antigen
breaks self-tolerance and stimulates a robust immune response.
Several approaches have attempted to improve natural HLA
class I-presented peptides and enhance their immunogenicity.
These methodologies revolve around either improving peptide
interactions with the HLA or the TCR.
Improving Peptide Antigens by Enhancing
MHC Binding
One relatively easy way to improve the antigenicity of a
peptide is to substitute the residues at primary HLA anchors if
these residues are suboptimal. The introduction of substitutions
at HLA anchor residue positions used to be a popular
approach for developing TAA-derived peptides with enhanced
immunogenicity for vaccination. This approach is relatively
simple as peptide binding motifs for the common HLAs
have been established for over 20 years. Most work has been
undertaken with HLA A2-restricted peptides where it is known
that the majority of tumour-derived peptides do not contain
an ideal HLA binding consensus. The use of anchor-modified
“heteroclitic” peptides in these systems is widespread [reviewed
in Cole et al. (44)]. The best-known example of such a
heteroclitic peptide is derived from the Melan-A/MART-1 where
the natural 10-mer epitope is EAAGIGILTV, as used in this
study. This natural sequence does not have an optimal anchor
residue at p2 for the HLA A2 restriction element. Substitution
of the p2 Alanine residue for the optimal Leucine residue
(45) produces the peptide ELAGIGILTV which was shown to
have considerably higher immunogenicity in vitro (30) and to
activate melanoma-reactive CD8 T-cells following vaccination
(46). While vaccination with the ELAGIGILTV peptide was
shown to induce much larger populations of antigen-specific
T-cells, these cells were inferior to the T-cells induced by
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TABLE 2 | Data collection and refinement statistics.
PDB code 6G3J
DATA COLLECTION
DLS Beamline I24
Space group C 1 2 1
Wavelength (Å) 0.96859
CELL DIMENSIONS
a, b, c (Å) 202.94, 50.28, 119.07
α, β, γ (◦) 90.0, 122.86, 90.0
Resolution (Å) 2.45–41.05
Outer Shell (Å) 2.51–2.45
Rmerge (%) 10.4 (115.5)
Rmeas (%) 12.3 (135.4)
CC1/2 0.993 (0.594)
I / σ I 9.1 (1.0)
Completeness (%) 98.7 (99.3)
Multiplicity 3.5 (3.6)
Unique reflections 37,034 (2,764)
Wilson B Factor (Å2) 61.8
REFINEMENT
R-work reflections 35,216
R-free reflections 1,818
Rwork/Rfree 22.3/27.0
R.M.S. DEVIATIONS
Bond lengths (Å) 0.018
Bond Angles (◦) 1.9
Coordinate Error 0.331
Mean B value (Å2) 84.8
RAMACHANDRAN STATISTICS
Favoured/Allowed/Outliers 725/27/5
(%) 95.8/3.6 0.7/
One crystal was used for determining each structure.
Figures in brackets refer to outer resolution shell.
Coordinate Estimated Standard Uncertainty error calculated based on maximum
likelihood statistics.
the natural sequence (47). T-cells induced by vaccination with
EAAGIGILTV and ELAGIGILTV are clonotypically distinct
(48). This diﬀerence was thought to be the cause of the poor
clinical results with the ELAGIGILTV analogue (35). Subsequent
work in our laboratory demonstrated that TCRs can diﬀerentiate
between natural and ELAGIGILTV anchor-modified peptides
enabling T-cells to exhibit a strong preference for either type of
antigen (44). Structural studies have confirmed that TCRs can
distinguish between EAAGIGILTV and ELAGIGILTV peptides
(15, 49). This cautionary tale demonstrates that T-cell clonotypes
induced by any APL-based immune intervention should be
carefully evaluated after ex vivo priming to ensure eﬃcacy prior
to studies in vivo.
Improving Antigens by Enhancing TCR
Binding
An alternative approach for improvement of T-cell epitopes
from TAA is to enhance their engagement with cognate TCRs.
Alteration of TCR contact residues has the advantage that the
resultant APL are highly likely to be viewed as “nonself ” and
may therefore have increased potential for breaking immune
tolerance. However, as for the above-mentioned peptide anchor
residue modification, the use of an APL also runs the risk of
inducing clonotypes that are ineﬀective at recognising the native
sequence. PS-CPL have been explored as a way of selecting such
“mimitopes” (19, 33, 50). This approach relies on the fact that
individual T-cells are capable of recognising millions of diﬀerent
peptides (50–52). Consequently, the chance of the natural antigen
being optimal for any given TCR is extremely small. PS-CPL data
can be combined with computational approaches to predict the
range of agonists that are recognised by any given T-cell (50, 53).
We recently used this technique to generate a non-natural D-
amino acid peptide that could be used to protect humanised
mice against a lethal challenge with influenza virus (54). The
best D-peptide agonist bore little resemblance to the optimal L-
peptide, underscoring the potential scope of TCRs to recognise
a wide range of chemically diﬀerent ligands. These results also
highlight that it is currently impossible to predict TCR ligands
without undertaking functional screening experiments. PS-CPL
approaches have been applied to cancer vaccination (19). A
cutaneous T-cell lymphoma (CTCL)-reactive HLA B8-restricted
CD8 T-cell clone was used to generate a mimitope that induced
populations of T-cells that lysed tumour cells in vitro (19).
Vaccination of two HLA B8+ CTCL patients with this mimitope
induced initial tumour regression in both patients (55) but direct
comparisons with the natural sequence, as undertaken in this
study, were not possible as the targeted TAA was unknown.
Substitution of the HLA A2-restricted, human carcinoembryonic
antigen (CEA)-derived epitope YLSGANLNL at position 6
(believed to be a TCR contact residue), to produce YLSGADLNL,
increased immunogenicity by two orders of magnitude when
tested in vivo (56). Unfortunately, it was subsequently shown that
most T-cells induced by the YLSGADLNL peptide recognised
the natural antigen poorly (57). Previous attempts to improve
TAA peptides have treated T-cells at the population level rather
than focussing on the most eﬀective clonotype(s) within the
population. A more promising strategy to improve antigens
for cancer vaccination might require identification of the most
eﬀective clonotypes and trying to specifically induce such T-cells.
This approach, christened ‘TCR Optimised Peptide Skewing Of
the Repertoire of T-cells’ (TOPSORT) was used to generate a
Melan-A/MART-1 analogue peptide, FATGIGIITV that primed
larger populations of T-cells then primed with the ELAGIGILTV
analogue in parallel in 6 of 10 donors as described in the Results
section (31). While these results were promising, the approach
only improved responses using a minority of HLA A2+ PBMC.
This deficiency was put down to there being a lack of the required
clonotype(s) within the PBMC where the approach failed to
show improvements (31). For the TOPSORT approach to be
considered for clinical use, it would require an APL that was
capable of generating improved T-cell responses in the majority–
and preferably all–individuals. Here, we sought to improve this
approach by starting with clonotypes that were derived from
TIL that were used to induce a complete lasting remission in a
metastatic melanoma patient.
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FIGURE 6 | HLA A2-MTSAIGILPV is a structural mimic of HLA A2-EAAGIGILTV that exhibits improved binding to HLA. (A) T2 cells (TAP deficient HLA A2+) were
incubated overnight in serum-free media with EAAGIGILTV and MTSAIGILPV at 1, 10, and 100µM, alongside a panel of control peptides including HLA A2 binding
peptides ELAGIGILTV (heteroclitic L at positon 2), GILGFVFTL (from M1 of influenza), HLA B*2705 binding peptide DRASFIKNL (from collagen) and HLA B*3501
HPVGEADYFEY (from EBV). Experiment was carried out in duplicate and results are expressed as the mean fluorescence intensity (MFI) of HLA A2 expression. The
dashed line shows the MFI staining in the absence of exogenously supplied peptide. Associated flow cytometry plots are displayed in Supplementary Figure 5.
(B) Structural analysis of the HLA A2-MTSAIGILPV complex compared to HLA A2-EAAGIGILTV. The HLA α1 helix is shown as grey cartoon with the MTSAIGILPV
(orange sticks) and EAAGIGILTV (green sticks) superimposed. Black arrows demonstrate the upward facing solvent exposed and downward facing buried residues in
each peptide. Boxes to the left show the interaction between the HLA A2 B-pocket (grey surface) and EAAGIGILTV (green cartoon and sticks) and MTSAIGILPV
(orange cartoon and sticks).
A Super-Agonist for a T-Cell Clone From a
TIL Success Primed a Larger
EAAGIGILTV-Specific T-Cell Response
Than the Natural Sequence From all 14
Healthy Donors Tested
As described above our previous attempt to skew the repertoire of
T-cells toward thosemore eﬀective at recognisingmelanoma cells
used the MEL5 T-cell clone that was grown from a healthy donor
to design an APL for T-cell priming was only partially successful.
This failure was attributed to some donors lacking the relevant
clonotypes that could be stimulated by the APL and cross-react
with the natural epitope presented at the melanoma cell surface.
Here, we refined the TOPSORT approach by selecting a T-cell
clone derived from the TIL infusion product of a melanoma
patient that was cured by TIL therapy and that persisted in the
patient blood long after complete remission. A PS-CPL screen
of the ST8.24 T-cell clone was used to generate a ranked list of
predicted super-agonist peptides. The top 10 predicted peptides
were tested for their ability to prime an HLA A2-EAAGIGILTV
tetramer positive T-cell population from the blood of five healthy
donors. An APL of sequence MTSAIGILPV was observed to
induce a significantly larger T-cell population than parallel assay
with the natural EAAGIGILTV in 5/5 donors (Figure 3).We next
examined how this peptide expanded EAAGIGILTV-specific
T-cells over 14 and 28 days from seven more HLA A2+
individuals and found that the MTSAIGILPV APL induced
substantially more HLA A2-EAAGIGILTV tetramer positive
cells. CSFE proliferation assays showed that EAAGIGILTV-
specific T-cells stimulated with MTSAIGILPV peptide exhibited
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FIGURE 7 | Super-agonist tetramer binds EAAGIGILTV specific T-cells with greater fluorescent intensity. (A) pMHC-tetramer staining of five EAAGIGILTV clones
derived from healthy donors (MEL5, CACTUS, EDDY and MANUELA) or a metastatic melanoma patient (ST8.24). The mean fluorescence intensity of staining (MFI) is
displayed for irrelevant (ALWGPDPAAA from preproinsulin), EAAGIGILTV and MTSAIGILPV tetramers. Tetramer staining was carried out using a standard protocol
(MEL5, CACTUS, and EDDY), with PKI (ST8.24) or with PKI + anti-PE 1◦ antibody + PE conjugated 2◦ antibody (MANUELA) in order to give clear EAAGIGILTV
tetramer staining (22). Line graphs indicate sensitivity to EAAGIGILTV peptide or MTSAIGILPV super-agonist at the concentrations indicated in an overnight activation
assay followed by MIP-1β ELISA. (B) pMHC tetramer staining of EAAGIGILTV or MTSAIGILPV peptide primed polyclonal CD8 T-cell populations isolated from healthy
donors 13 and 14. T-cells were stained using an optimised protocol: PKI + PE tetramer + 1◦ + 2◦ antibodies. The percentage of gated cells and their MFI is
displayed. (C) Accumulated mean florescent intensity (MFI) of all EAAGIGILTV-CD8 T-cell clones and polyclonal CD8 T-cell populations used. The difference in MFI
between EAAGIGILTV-tetramer and MTSAIGILPV-tetramer staining was statistically significant (P = 0.003, paired one-tailed T-test).
enhanced proliferation compared to those primed with the
natural antigen in parallel (Figure 4). We were unable to look at
longer timepoints than 28 days as some cells started to die after 30
days, most likely due to a requirement for restimulation through
the TCR.
MTSAIGILPV Super-Agonist Peptide
Exhibits Improved Binding to HLA A2
The MTSAIGILPV peptide was shown to exhibit superior
binding to HLA A2 compared to the natural EAAGIGILTV
sequence. Structural analysis attributed this enhanced binding
to the longer side chain of threonine at peptide residue 2
(compared to alanine in EAAGIGILTV) being able to extend
deeper into the HLA A2 B-pocket. This increased interaction
with the restricting HLA is likely to contribute to why the
MTSAIGILPV exhibits increased immunogenicity in all 14
donors and both patients tested. Despite the very diﬀerent
sequence MTSAIGILPV was shown to be a close structural
mimic of EAAGIGILTV, providing an explanation for the strong
cross-reactivity between these ligands. Indeed, both peptides
induced EAAGIGILTV-specific TCRs that predominantly used
the TRAV12-2 gene (Supplementary Figure 6), likely due to
the high level of similarity in antigenic features in both
peptides, revealed from the crystal structures. Structural
studies have demonstrated that the predominant contacts
between a TRAV12-2 EAAGIGILTV-specific TCR were made
with germline encoded CDR regions. This mode of binding
explains the biased usage of TRAV12-2 by EAAGIGILTV-
specific TCRs and may provide an explanation for why
T-cells induced with the MTSAIGILPV peptide cross-react
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FIGURE 8 | CD8 T-cells from melanoma patients primed with super-agonist MTSAIGILPV resulted in superior autologous melanoma killing. (A) 4 × 105 CD8 T-cells
from metastatic melanoma patients MM909.37 and MM1413.12 were primed with WT EAAGIGILTV or super agonist MTSAIGILPV peptides. MM909.37 is now
deceased having not responded to therapy. EAAGIGILTV and irrelevant (ALWGPDPAAA from preproinsulin) tetramer staining was performed at day 28, with
percentage of tetramer+ cells displayed. (B) Chromium release cytotoxicity assay performed for the T-cell lines from MM909.37 using autologous melanoma. The
T-cell line to melanoma cell ratio displayed is based on total T-cell number. Insufficient cells were available from patient MM1413.12 to perform the killing assay.
(C) Cytotoxicity assay as in (B), but with cell numbers adjusted according to EAAGIGILTV tetramer positivity shown in (A), to give two EAAGIGILTV tetramer+ cell per
three autologous melanoma cells, for both the EAAGIGILTV and MTSAIGILPV primed T-cell lines (thus a different number of total cells was used from each primed
line). P-values are displayed for an unpaired one-tailed t-test.
with the EAAGIGILTV peptide. The increased HLA binding
of the MTSAIGILPV peptide is unlikely to explain why
the T-cells primed from the PBMC of a melanoma patient
prior to treatment with this APL were better at recognising
the autologous melanoma line than those induced by the
natural antigen.
EAAGIGILTV Specific T-Cells Bind HLA
A2-MTSAIGILPV With Increased Avidity
In addition to the improved binding of the MTSAIGILPV
peptide to HLA A2, clonal, and polyclonal T-cells bound HLA
A2-MTSAIGILPV tetramer with greater intensity, suggesting
that the associated TCRs recognised the agonist peptide with
increased aﬃnity compared to HLA A2-EAAGIGILTV. Taken
together, these data suggest that T-cells received greater antigenic
stimulus upon priming with MTSAIGILPV peptide. This
enhanced stimulus presumably accounts for the increased T-cell
expansion observed across all 16 subjects used for this study
compared to the natural EAAGIGILTV sequence in parallel
assays. Further structural and biophysical studies will be required
to formally confirm that the MTSAIGILPV peptide binds more
readily to cognate TCRs.
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MTSAIGILPV Primed T-Cells From Blood
That Exhibit Improved Killing of Melanoma
Tumour
Importantly, the greater population of EAAGIGILTV-specific
T-cells expanded from the PBMCs of healthy donors and a
melanoma patient prior to treatment, using the MTSAIGILPV
peptide, exhibited superior killing of cancer cells. Thus, this APL
was able to induce T-cells in greater quantity. In one case we were
able to demonstrate that the MTSAIGILPV induced T-cells of
greater quality on a per cell basis.
Summary
In summary, we used a T-cell clone derived from the TIL
of a melanoma patient that persisted in patient PBMC after
long-lasting tumour remission to generate a novel APL super-
agonist peptide with the sequenceMTSAIGILPV. This APL was
capable of inducing greater numbers of T-cells specific for the
natural antigen EAAGIGILTV from the PBMC of 14/14 healthy
donors and 2/2 patients tested compared to the natural antigen
itself. Importantly, the APL-generated T-cells were shown to
kill tumour cells with greater potency than those induced by
the natural epitope. The greater proliferation of cognate T-
cells induced by the MTSAIGILPV sequence might reflect its
greater binding to HLA. This peptide also engages host TCRs
with better eﬃciency and thereby could encompass an enhanced
ability to break self-tolerance mechanisms. The diﬀerences in
EAAGIGILTV-specific clonotypes induced by MTSAIGILPV
suggests that this APL is viewed diﬀerently by TCRs despite its
structural similarity. Further work will be required to determine
how this sequence has potential to induce T-cells in greater
quantity that can exhibit enhanced function at the single cell level.
Overall, our data suggest that theMTSAIGILPV sequence might
make a promising candidate for peptide vaccination of HLA A2+
melanoma patients.
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